Wall Street analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to post earnings of ($1.39) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings. The lowest EPS estimate is ($1.50) and the highest is ($1.28). Wave Life Sciences posted earnings of ($1.28) per share during the same quarter last year, which suggests a negative year over year growth rate of 8.6%. The firm is scheduled to announce its next earnings results on Friday, November 8th.

According to Zacks, analysts expect that Wave Life Sciences will report full-year earnings of ($5.38) per share for the current fiscal year, with EPS estimates ranging from ($5.88) to ($5.01). For the next fiscal year, analysts expect that the company will post earnings of ($4.51) per share, with EPS estimates ranging from ($5.45) to ($3.32). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Monday, July 29th. The company reported ($1.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.11). Wave Life Sciences had a negative return on equity of 120.41% and a negative net margin of 861.41%. The company had revenue of $7.63 million during the quarter, compared to analyst estimates of $15.76 million.

Several equities research analysts recently weighed in on the company. BidaskClub upgraded Wave Life Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, August 8th. Cowen restated a “hold” rating on shares of Wave Life Sciences in a research report on Tuesday, July 30th. HC Wainwright restated a “buy” rating on shares of Wave Life Sciences in a research report on Wednesday, July 31st. ValuEngine upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Mizuho restated a “buy” rating and set a $65.00 price objective on shares of Wave Life Sciences in a research report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $49.50.

In other Wave Life Sciences news, insider Michael A. Panzara sold 3,058 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $26.94, for a total value of $82,382.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 39.70% of the company’s stock.

Large investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Wave Life Sciences by 6.7% during the 2nd quarter. BlackRock Inc. now owns 1,811,996 shares of the company’s stock worth $47,275,000 after acquiring an additional 113,292 shares during the period. Virtus ETF Advisers LLC increased its stake in shares of Wave Life Sciences by 93.3% in the 2nd quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock valued at $271,000 after purchasing an additional 5,014 shares during the last quarter. Athanor Capital LP bought a new position in shares of Wave Life Sciences in the 2nd quarter valued at $566,000. Northern Trust Corp increased its stake in shares of Wave Life Sciences by 2.0% in the 2nd quarter. Northern Trust Corp now owns 265,291 shares of the company’s stock valued at $6,922,000 after purchasing an additional 5,145 shares during the last quarter. Finally, Matisse Capital increased its stake in shares of Wave Life Sciences by 34.8% in the 2nd quarter. Matisse Capital now owns 60,826 shares of the company’s stock valued at $1,587,000 after purchasing an additional 15,715 shares during the last quarter. Hedge funds and other institutional investors own 86.28% of the company’s stock.

WVE traded down $0.31 on Wednesday, hitting $21.06. The company had a trading volume of 2,207 shares, compared to its average volume of 387,548. The stock’s fifty day simple moving average is $23.56. Wave Life Sciences has a 1-year low of $18.16 and a 1-year high of $56.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.33 and a current ratio of 2.33. The company has a market capitalization of $731.89 million, a PE ratio of -4.15 and a beta of 0.81.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.